Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064052 | 0.84 | MAPT (0.45) | MAPTALDH1A1TDP1MEN1HPGD | |
| SCHEMBL11956683 | 0.80 | TSHR (0.40) | ALDH1A1HPGDKMT2AHSD17B10TSHR | |
| SCHEMBL3065013 | 0.78 | ALDH1A1 (0.50) | MAPTALDH1A1GAATDP1MEN1 | |
| SCHEMBL5147549 | 0.73 | MAPT (0.50) | MAPTALDH1A1GAATDP1MEN1 | |
| SCHEMBL1999063 | 0.72 | NR1H2 (0.52) | MAPTALDH1A1GAATDP1HPGD | |
| SCHEMBL3776114 | 0.71 | ALDH1A1 (0.48) | MAPTALDH1A1GAATDP1MEN1 | |
| SCHEMBL5748508 | 0.71 | MAPT (0.53) | MAPTALDH1A1GAATDP1KMT2A | |
| SCHEMBL5913906 | 0.70 | ALDH1A1 (0.60) | MAPTALDH1A1GAATDP1HPGD | |
| SCHEMBL25376120 | 0.69 | MAPT (0.46) | MAPTALDH1A1GAATDP1MEN1 | |
| SCHEMBL9049112 | 0.69 | ALDH1A1 (0.38) | MAPTALDH1A1GAAMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242275-B2 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8242275-B2 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8232391-B2 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-31 | — | — | US | disclosed |
| US-8232391-B2 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-31 | — | — | US | disclosed |
| US-7842810-B2 | 2,3-Dihydro-benzo[1,4]dioxine-6-carboxylic acid [2-(6-methoxy-quinolin-4-yl)-4,5,6,7-tetrahydro-2H-indazol-5-yl]-amide | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-30 | — | — | US | disclosed |
| US-7842810-B2 | 2,3-Dihydro-benzo[1,4]dioxine-6-carboxylic acid [2-(6-methoxy-quinolin-4-yl)-4,5,6,7-tetrahydro-2H-indazol-5-yl]-amide | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-30 | — | — | US | disclosed |
| US-20100280240-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-11-04 | — | — | US | disclosed |
| US-20100280240-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-11-04 | — | — | US | disclosed |
| US-20100274005-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-10-28 | — | — | US | disclosed |
| US-20100274005-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-10-28 | — | — | US | disclosed |
| US-20100274004-A1 | BICYCLIC PIRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-10-28 | — | — | US | disclosed |
| US-20100274004-A1 | BICYCLIC PIRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-10-28 | — | — | US | disclosed |
| EP-1863483-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-12 | — | — | EP | disclosed |
| US-20060223810-A1 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | US | disclosed |
| WO-2006105289-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274005-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | NOD2, BAK1, CASP3 | MAPT 4108/4885ALDH1A1 3885/4885GAA 2502/4885 |
| US-20060223810-A1 | Bicyclic pyrazole compounds as antibacterial agents | NOD2, BAK1, CASP3 | MAPT 4108/4885ALDH1A1 3885/4885GAA 2502/4885 |
| US-20100274004-A1 | BICYCLIC PIRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | PIR, BAK1, TMBIM6 | MAPT 4598/4885ALDH1A1 3228/4885GAA 3798/4885 |
| US-20100280240-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | NOD2, BAK1, CASP3 | MAPT 4108/4885ALDH1A1 3885/4885GAA 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.